TNG462 in MTAP-deleted Solid Tumors including MPNST


Agents: TNG462
Phase I/II
Status Recruiting
Sponsor Tango Therapeutics


Further information on


Phase I/II study in solid tumor patients with a specific genetic mutation, a MTAP deletion, including malignant peripheral nerve sheath tumors (MPNST)

WHO is the trial for?

  • Patients of 18 years or older
  • Patients must have a diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor
  • Patients must have received prior standard therapy when applicable
  • Overall health of the patient must be good (ECOG performance score of 0 or 1)

WHAT is the key question that this trial is attempting to answer?

This trial assesses which is the optimal dosage of TNG462 in solid tumors with MTAP deletion (phase 1 of the study) and if the drug can lead to tumor shrinkage or stablize the disease (phase 2). In the phase 2 part, a specific treatment arm for MPNST patients in included.

WHY patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN will the trial be open?

This study is currently open for recruitment.

WHERE is the trial available?

The trial is being conducted currently only in the US, but further sites are planned to be opened in France and Spain.

For further information please check here.

Study contact:

STUDY DESIGN: What does the study look like?

This study has two phases: In phase 1 of this trial, the optimal dosage of TNG462 is assessed. In phase 2, this dosage will be given to patients with different kinds of solid tumors including malignant peripheral nerve sheath tumors (MPNST) in order to see if the drug can stablize the disease or shrink the tumor.

HOW do I get more information?

Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients. If there are no such organization in your country, please email us for more information:

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.